After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling move by a company that was on the verge of being purchased for $4.3 billion just two years ago.
The filing follows a protracted period in which the drug maker haggled with lenders and fended off shareholder lawsuits, which were prompted after Fresenius Kabi walked away from a deal to buy the company. The acquisition fell apart after Fresenius found what it described as “material breaches” in manufacturing standards at Akorn facilities.
About the Author Reprints
May one observe that “The business has an “underlying strength” makes for an interesting quote. Where exactly do they hide it?